The role of nuclear factor kappa B and nitric oxide interaction in heart remodelling

Journal of Hypertension

Volumn 28, Issue SUPPL. 1, 2010, Pages

  Pechanova, Olga ^a   Simko, Fedor ^b  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

^b Faculty of Natural Sciences   (Slovakia)

Author keywords

fibrosis; hypertrophy; nitric oxide; nuclear factor kappa B; reactive oxygen species

Indexed keywords

ANGIOTENSIN II; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 6; NEUROHORMONE; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NORADRENALIN; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; TUMOR NECROSIS FACTOR ALPHA;

CARDIOVASCULAR SYSTEM; HEART HEMODYNAMICS; HEART HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HUMAN; HYPOTENSION; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW;

EID: 77957287600     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000388493.81578.b1     Document Type: Review

References (57)

1. Cuspidi C, Ciulla M, Zanchetti A. Hypertensive myocardial fibrosis. Nephrol Dial Transplant 2006; 21:20-23.
2. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev 1999; 79:215-262.
3. Dorn GW, Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest 2005; 115:527-537.
4. Sekiguchi K, Li X, Coker M, Flesch M, Barger PM, Sivasubramanian N, Mann DL. Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure. Cardiovasc Res 2004; 63:433-442.
5. Zhou MS, Schulman IH, Raij L. Vascular inflammation, insulin resistance, and endothelial dysfunction in salt-sensitive hypertension: role of nuclear factor kappa B activation. J Hypertens 2010; 28:527-535.
6. Orr AW, Sanders JM, Bevard M, Coleman E, Sarembock IJ, Schwartz MA. The subendothelial extracellular matrix modulates NF-kappaB activation by flow: a potential role in atherosclerosis. J Cell Biol 2005; 169:191-202.
7. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002; 3:221-227.
8. Grumbach IM, Chen W, Mertens SA, Harrison DG. A negative feedback mechanism involving nitric oxide and nuclear factor kappa-B modulates endothelial nitric oxide synthase transcription. J Mol Cell Cardiol 2005; 39:595-603.
9. Rockman HA, Koch WJ, Lefkowitz RJ. Seven-transmembrane-spanning receptors and heart function. Nature 2002; 415:206-212.
10. Molkentin JD, Dorn GW. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu Rev Physiol 2001; 63:391-426.
11. Hedayat M, Mahmoudi MJ, Rose NR, Rezaei N. Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev 2010. April 20, doi: 10.1007/s10741-010-9168-4.
12. Li J, Brasier AR. Angiotensinogen gene activation by angiotensin II is mediated by the rel A (nuclear factor-kappaB p65) transcription factor: one mechanism for the renin angiotensin system positive feedback loop in hepatocytes. Mol Endocrinol 1996; 10:252-264.
13. Flesch M, Hoper A, DellItalia L, Evans K, Bond R, Peshock R, et al. Activation and functional significance of the renin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor. Circulation 2003; 108:598-604.
14. Simko F, Pechanova O. Recent trends in hypertension treatment: perspectives from animal studies. J Hypertens 2009; 27 (Suppl. 6): S1-S4.
15. Hernandez-Presa M, Bustos C, Ortega M, Tunon J, Renedo G, Ruiz-Ortega M, Egido J. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kB activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997; 95:1532-1541.
16. Nakamura K, Fushimi K, Kouchi H, Mihara K, Miyazaki M, Ohe T, Namba M. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation 1998; 98:794-799.
17. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases role of oxidative stress in cardiovascular diseases. J Hypertens 2000; 18:655-673.
18. Kang BY, Mehta JL. Rosuvastatin attenuates Ang II-mediated cardiomyocyte hypertrophy via inhibition of LOX-1. J Cardiovasc Pharmacol Ther 2009; 14:283-291.
19. Brasier AR, Li J. Mechanisms for inducible control of angiotensinogen gene transcription. Hypertension 1996; 27:465-475.
20. Tak PP, Firestein GS. NF-kappaB: a key role in inflammatory diseases. J Clin Invest 2001; 107:7-11.
21. Parohova J, Vrankova S, Barta A, Kovacsova M, Pechanova O. The crosstalk of nuclear factor kappaB and nitric oxide in the brain. Activitas Nervosa Superior Rediviva 2009; 51 (3-4):123-126.
22. Frangogiannis NG. The immune system and cardiac repair. Pharmacol Res 2008; 58:88-111.
23. Stancovski I, Baltimore D. NF-kappaB activation: the I kappaB kinase revealed? Cell 1997; 91:299-302.
24. Kupatt C, Habazettl H, Goedecke A, Wolf DA, Zahler S, Boekstegers P, et al. Tumor necrosis factor-alpha contributes to ischemia- and reperfusioninduced endothelial activation in isolated hearts. Circ Res 1999; 84:392-400.
25. Gupta S, Purcell NH, Lin A, Sen S. Activation of nuclear factor-kappaB is necessary for myotrophin-induced cardiac hypertrophy. J Cell Biol 2002; 159:1019-1028.
26. Sen CK, Roy S. Relief from a heavy heart: redox-sensitive NF-kB as a therapeutic target in managing cardiac hypertrophy. Am J Physiol Heart Circ Physiol 2005; 289:H17-H19.
27. De Keulenaer GW, Wang Y, Feng Y, Muangman S, Yamamoto K, Thompson JF, et al. Identification of IEX-1 as a biomechanically controlled nuclear factor-kB target gene that inhibits cardiomyocyte hypertrophy. Circ Res 2002; 90:690-696.
28. Collins T. Endothelial nuclear factor-kB and the initiation of the atherosclerotic lesion. Lab Invest 1993; 68:499-508.
29. Tirziu D, Simons M. Endothelium-driven myocardial growth or nitric oxide at the crossroads. Trends Cardiovasc Med 2008; 18:299-305.
30. Klimaschewski L, Kummer W, Mayer B, Couraud JY, Preissler U, Philippin B, Heym C. Nitric oxide synthase in cardiac nerve fibers and neurons of rat and guinea pig heart. Circ Res 1992; 71:1533-1537.
31. Sosunov AA, Hassall CJS, Loesch A, Turmaine M, Burnstock G. Nitric oxide synthase-containing neurons and nerve fibres within cardiac ganglia of rat and guinea pig: an electron-microscopic immunocytochemical study. Cell Tissue Res 1996; 284:19-28.
32. Feron O, Balligand JL. Caveolins and the regulation of endothelial nitric oxide synthase in the heart. Cardiovasc Res 2006; 69:788-797.
33. Shah AM, MacCarthy PA. Paracrine and autocrine effects of nitric oxide on myocardial function. Pharmacol Ther 2000; 86:49-86.
34. Michel T. The complexities of coupling nitric oxide synthase pathways in the heart. Circulation 2010; 121:484-486.
35. Williams JC, Armesilla AL, Mohamed TM, Hagarty CL, McIntyre FH, Schomburg S, et al. The sarcolemmal calcium pump, alpha-1 syntrophin, and neuronal nitric-oxide synthase are parts of a macromolecular protein complex. J Biol Chem 2006; 281:23341-23348.
36. Paulus WJ. The role of nitric oxide in the failing heart. Heart Fail Rev 2001; 6:105-118.
37. Massion PB, Balligand JL. Relevance of nitric oxide for myocardial remodeling. Curr Heart Fail Rep 2007; 4:18-25.
38. Smith RS Jr, Agata J, Xia CF, Chao L, Chao J. Human endothelial nitric oxide synthase gene delivery protects against cardiac remodeling and reduces oxidative stress after myocardial infarction. Life Sci 2005; 76:2457-2471.
39. Pechanova O, Bernatova I, Pelouch V, Simko F. Protein remodelling of the heart in NO-deficient hypertension: the effect of captopril. J Mol Cell Cardiol 1997; 29:3365-3374.
40. Bernatova I, Pechanova O, Kristek F. Mechanism of structural remodelling of the rat aorta during long-term NG-nitro-L-arginine methyl ester treatment. Jpn J Pharmacol 1999; 81:99-106.
41. Kitamoto S, Egashira K, Kataoka C, Koyanagi M, Katoh M, Shimokawa H, et al. Increased activity of nuclear factor-kappaB participates in cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis in rats. Circulation 2000; 102:806-812.
42. Vrankova S, Barta A, Parohova J, Pechanova O. Could NF-kappa B play a role in blood pressure regulation? Focused on L-NAME-induced hypertension. J Hypertens 2009; 27 (Suppl. 4):S140.
43. Pechanova O, Simko F. Chronic antioxidant therapy fails to ameliorate hypertension: potential mechanisms behind. J Hypertens 2009; 27 (Suppl. 6):S32-S36.
44. Peng HB, Libby P, Liao JK. Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem 1995; 270:14214-14219.
45. Okamoto T, Valacchi G, Gohil K, Akaike T, van der Vliet A. S-nitrosothiols inhibit cytokine-mediated induction of matrix metalloproteinase-9 in airway epithelial cells. Am J Respir Cell Mol Biol 2002; 27:463-473.
46. Marshall HE, Stamler JS. Inhibition of NF-kappa B by S-nitrosylation. Biochemistry 2001; 40:1688-1693.
47. Zhen J, Lu H, Wang XQ, Vaziri ND, Zhou XJ. Upregulation of endothelial and inducible nitric oxide synthase expression by reactive oxygen species. Am J Hypertens 2008; 21:28-34.
48. Kojsová S, Jendeková L, Zicha J, Kunes J, Andriantsitohaina R, Pechánová O. The effect of different antioxidants on nitric oxide production in hypertensive rats. Physiol Res 2006; 55 (Suppl. 1):S3-S16.
49. Kobayashi N, Mita S, Yoshida K, Honda T, Kobayashi T, Hara K, et al. Celiprolol activates eNOS through the PI3K-Akt pathway and inhibits VCAM-1 via NF-kappaB induced by oxidative stress. Hypertension 2003; 42:1004-1013.
50. Manea A, Manea SA, Gafencu AV, Raicu M. Regulation of NADPH oxidase subunit p22(phox) by NF-kB in human aortic smooth muscle cells. Arch Physiol Biochem 2007; 113 (4-5):163-172.
51. Pechánová O, Simko F. The role of nitric oxide in the maintenance of vasoactive balance. Physiol Res 2007; 56 (Suppl. 2):S7-S16.
52. Harrison CB, Drummond GR, Sobey CG, Selemidis S. Evidence that nitric oxide inhibits vascular inflammation and superoxide production via a p47phox-dependent mechanism in mice. Clin Exp Pharmacol Physiol 2009; 37:429-434.
53. Muzaffar S, Shukla N, Bond M, Sala-Newby G, Angelini GD, Newby AC, Jeremy JY. Acute inhibition of superoxide formation and Rac1 activation by nitric oxide and iloprost in human vascular smooth muscle cells in response to the thromboxane A2 analogue, U46619. Prostaglandins Leukot Essent Fatty Acids 2008; 78:247-255.
54. Vrankova S, Parohova J, Barta A, Janega P, Simko F, Pechanova O. The effect of nuclear factor kappaB inhibition on L-NAME-induced hypertension and cardiovascular remodelling. J Hypertens 2010; 28 (Suppl. 1):S45-S49.
55. Misra A, Haudek SB, Knuefermann P, Vallejo JG, Chen ZJ, Michael LH, et al. Nuclear factor-kappaB protects the adult cardiac myocyte against ischemia-induced apoptosis in a murine model of acute myocardial infarction. Circulation 2003; 108:3075-3078.
56. Zelarayan L, Renger A, Noack C, Zafiriou MP, Gehrke C, van der Nagel R, et al. NF-kappaB activation is required for adaptive cardiac hypertrophy. Cardiovasc Res 2009; 84:416-424.
57. Sármán B, Skoumal R, Leskinen H, RysäJ, Ilves M, Soini Y, et al. Nuclear factor-kappaB signaling contributes to severe, but not moderate, angiotensin II-induced left ventricular remodeling. J Hypertens 2007; 25:1927-1939.